Observational Study of NovoPen Echo® on Safety and Treatment Satisfaction in Children and Adolescents With Type 1 Diabetes

A Multicentre, Observational Study of NovoPen Echo® on Safety and Treatment Satisfaction of Insulin Therapy in Children and Adolescents With Diabetes Mellitus

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01180530

Acronym

REMIND™

Enrollment

358

Registered

2010-08-12

Start date

2010-10-31

Completion date

2011-03-31

Last updated

2017-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Delivery Systems, Diabetes, Diabetes Mellitus, Type 1

Brief summary

This study is conducted in Asia, Europe and North America. The aim of this observational study is to evaluate the safety of NovoPen Echo® by collecting safety information (incidence of technical complaints related to adverse reactions). Study duration: 12-18 weeks.

Interventions

DEVICENovoPen Echo®

Prescribed insulin treatment delivered by NovoPen Echo®

Study design

Observational model

OTHER

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

2 Years to 18 Years

Healthy volunteers

Inclusion criteria

* Children/adolescents with type 1 diabetes mellitus * After the participating physician's decision has been made to initiate treatment with NovoPen Echo®, any patient who meets all the inclusion criteria and does not meet any of the

Exclusion criteria

, is eligible to participate * Use of insulin pen or syringes for at least 12 months

Design outcomes

Primary

Measure	Time frame
The incidence of technical complaints related to adverse reactions	after 12-18 weeks (end of study)

Countries

Canada, Finland, Israel, Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026